We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.30 | 0.68% | 44.24 | 44.47 | 43.728 | 43.87 | 13,247,479 | 00:58:24 |
From May 2019 to May 2024
By Colin Kellaher
Biogen Inc. (BIIB) Friday said it is ending development of gosuranemab for the brain disorder progressive supranuclear palsy and other primary tauopathies after a phase 2 study missed its primary endpoint.
The Cambridge, Mass., biopharmaceutical company said the main endpoint, as measured by the progressive supranuclear palsy rating scale at week 52, wasn't statistically significant, and said the study didn't show efficacy on key clinical secondary endpoints.
Biogen, which licensed gosuranemab from Bristol-Myers Squibb Co. (BMY), said it will continue a Phase 2 study of the drug for mild cognitive impairment due to Alzheimer's disease or mild AD, given differences in disease pathology.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 13, 2019 08:00 ET (13:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
